Skip to main content

Table 1 Participant characteristics at baseline according to sleep disturbance

From: Longitudinal associations between sleep disturbance and disease severity in patients with COPD

 Total
(N = 157)
Sleep disturbance
(n = 74)
No sleep disturbance
(n = 83)
Unadjusted p-value
Age, year, mean (SD)66.3 (6.4)66.5 (6.2)66.1 (6.5)0.67
Sex, male, n (%)85 (54.1%)44 (59.4%)41 (49.4%)0.21
White, n (%)151 (96.2%)70 (94.6%)81 (97.5%)0.33
BMI, mean (SD)27.6 (4.1)26.9 (4.0)28.2 (4.2)0.04
Pack years, mean (SD)64.8 (34.1)66.9 (34.2)62.9 (34.1)0.46
Current smoker, n (%)62 (39.5%)35 (47.3%)27 (32.5%)0.06
Supplemental oxygen use, n (%)9 (5.7%)5 (6.8%)4 (4.8%)0.60
ICS use, n (%)8 (5.1%)6 (8.1%)2 (2.4%)0.11
OCS use,a n (%)40 (25.5%)20 (27.0%)20 (24.1%)0.67
GOLD stage, n (%)
 Stage 146 (29.3%)20 (27.0%)26 (31.3%)0.77
 Stage 287 (55.4%)42 (63.5%)45 (54.2%) 
 Stage 321 (13.4%)10 (13.5%)11 (13.3%) 
 Stage 43 (1.9%)2 (2.7%)1 (1.2%) 
GOLD ABCD group, n (%)
 Group A106 (67.5%)47 (63.5%)59 (71.1%00.64
 Group B26 (16.6%)13 (17.6%)13 (15.7%0 
 Group C14 (8.9%)7 (9.5%)7 (8.4%) 
 Group D11 (7.0%)7 (9.5%)4 (4.8%) 
Comorbidities, n (%)
 Diabetes9 (5.7%)3 (4.2%)6 (7.2%)0.42
 Hyperlipidemia84 (53.5%)39 (53.4%)45 (55.6%)0.79
 Cancer25 (15.9%)8 (10.8%)17 (20.5%)0.10
 Asthma17 (10.8%)30 (40.5%)20 (24.7%)0.32
 GERD50 (31.8%)10 (13.9%)7 (8.8%)0.04
 Bronchitis75 (47.8%)42 (60.0%)33 (42.3%)0.03
BDI-II category, n (%)
 Minimal/Mild151 (96.2%)69 (93.2%)82 (98.8%)0.07
 Moderate/ Severe6 (3.8%)5 (6.8%)1 (1.2%)0.56
 FEV1 pp., mean (SD)69.3 (18.4)8.4 (19.0)70.2 (18.1)0.40
 mMRC, mean (SD)1.1 (0.9)1.1 (1.1)0.9 (0.9)0.005
 SGRQ, mean (SD)25.0 (17.2)29.0 (18.1)21.4 (15.6)0.72
 ISWT distance (m), mean (SD)399.6 (146.7)394.9 (141.8)403.6 (152.0)0.58
 RV pp., mean (SD)138.4 (35.9)140.1 (34.8)136.8 (37.0)0.99
 RV/TLC, mean (SD)0.49 (0.10)0.49 (0.10)0.49 (0.10)0.15
 DLCO pp., mean (SD)66.9 (19.8)64.5 (21.6)69.1 (18.0)0.56
  1. BDI-II Beck Depression Inventory-II, BMI body mass index, FEV1pp forced expiratory volume in 1 s percent predicted, GERD gastroesophageal reflux disease, SD standard deviation, mMRC modified Medical Research Council scale, SGRQ St. George’s Respiratory Questionnaire, ISWT = Incremental shuttle walk test, RV pp residual capacity percent predicted, DLCO pp diffusion capacity for carbon monoxide percent predicted
  2. aOral steroid use, temporary short-term use in past 6 months